Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Aug 19;20(5):C19-21.
doi: 10.1530/ERC-13-0243. Print 2013 Oct.

IGF2 revs the steroidogenesis engine

Clay E S Comstock  1 , Karen E Knudsen
Affiliations
Comment

IGF2 revs the steroidogenesis engine

Clay E S Comstock et al. Endocr Relat Cancer. .

Abstract

Molecular understanding of how prostate cancers evade hormone therapy greatly increased over the last several years, and the realization that de novo steroidogenesis plays a significant role in tumor progression and therapeutic bypass has led to development of promising new therapeutics. In the April 2013 issue of Endocrine-Related Cancer, Lubik et al. revealed a new molecular pathway by which the IGF2 can ignite the de novo steroidogenesis engine and promote molecular events associated with tumor progression.

Keywords: IGF2; steroidogenesis.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Comment on

  • IGF2 increases de novo steroidogenesis in prostate cancer cells.
    Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, Hendy SC, Adomat HH, Gleave ME, Pollak M, Herington A, Nelson CC. Lubik AA, et al. Endocr Relat Cancer. 2013 Mar 22;20(2):173-86. doi: 10.1530/ERC-12-0250. Print 2013 Apr. Endocr Relat Cancer. 2013. PMID: 23319492

References

    1. Bergman D, Halje M, Nordin M, Engstrom W. Insulin-like growth factor 2 in development and disease: a mini-review. Gerontology. 2012;59:240–249. doi: 10.1159/000343995. - DOI - PubMed
    1. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology. 2008;8:440–448. doi: 10.1016/j.coph.2008.07.005. - DOI - PMC - PubMed
    1. Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Molecular and Cellular Endocrinology. 2012;360:3–13. doi: 10.1016/j.mce.2011.09.046. - DOI - PMC - PubMed
    1. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism. 2010;21:315–324. doi: 10.1016/j.tem.2010.01.002. - DOI - PMC - PubMed
    1. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research. 2008;68:6407–6415. doi: 10.1158/0008-5472.CAN-07-5997. - DOI - PubMed

Publication types